monovalent avian influenza virus-like particle H7N9 plus adjuvant 1

This is a **recombinant virus-like particle (VLP) vaccine** targeting avian influenza A (H7N9), formulated as a monovalent VLP representing the hemagglutinin (HA) antigen from the H7N9 strain A/Anhui/1/2013, and combined with an unspecified adjuvant, referred to as "adjuvant 1." VLPs are non-infectious nanoparticles that mimic the external structure of the influenza virus, stimulating both humoral and cellular immune responses. In clinical studies, use of adjuvant with H7N9 VLPs significantly increased immunogenicity compared to non-adjuvanted formulations, improving hemagglutination inhibition (HI) antibody titers and the breadth of immunity[1][3][4][7]. Matrix-M1 (a saponin-based adjuvant used in some studies) and ISCOMATRIX (another saponin-based adjuvant) have been studied for this purpose, but the specific identity of "adjuvant 1" in this context is not detailed. Developed primarily for pandemic influenza preparedness to protect against H7N9 virus infection, including pandemic situations and high-risk populations[1][3][4][7].

Other names

monovalent A/Anhui/1/2013 H7N9 VLP plus adjuvant 1